( Diversity of Abstracts Reflects Continu...)Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting,Health

WOODCLIFF LAKE, N.J., May 31, 2007 /PRNewswire/ -- Eisai announced today that several abstracts covering clinical data about their oncology pipeline compounds have been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. ASCO takes place in Chicago from June 1-5, 2007.

These abstracts reveal a growing and diverse oncology clinical development program at Eisai. In addition to the variety of oncology product classes under investigation, these compounds are being studied in advanced diseases where there remains considerable unmet medical need, particularly in refractory metastatic breast cancer, advanced non-small cell lung cancer, and advanced ovarian cancer.

The following abstracts highlight data from pipeline compounds that have been accepted for presentation at this year's ASCO meeting.

    Product        Abstract Details                        Location Details


    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389) Halichondrin B Analog in        AM - 1:00 PM

    (E7389)        Patients with Refractory Breast Cancer  Location: S403

    Abstract No:   Poster Number: 21

    1034



    Eribulin       Phase II Study of Eribulin Mesylate     June 2, 2007 8:00

    Mesylate       (E7389), a Mechanistically Novel        AM - 1:00 PM

    (E7389)        Inhibitor of Microtubule Dynamics,      Location: E451a

    Abstract No:   in Patients with Advanced Non-Small

    7546           Cell Lung Cancer (nsclc)

                   Poster Number: 20



    MORAb-003      Novel Phase II Study Design of          June 2, 2007

    Abstract No:   MORAb-003, a Monoclonal Antibody        2:00 PM - 6:00 PM

    5583           against Folate Receptor Alpha in        Location: S Hall A2

                   Platinum-Sensitive Ovarian Cancer

                   in First Relapse

    
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ESMO Conference